AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 84_CD Form_NN 20-F_JJ Information_NN 2004_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 6Dividends_NNS to_TO shareholders_NNS 2004 2003 2002 2004_CD 2003_CD 2002_CD Per_IN Per_IN Per_IN share_NN share_NN share_NN $_$ m_CD $_$ m_CD $_$ m_CD Interim_NNP ,_, paid_VBN on_IN 20_CD September_NNP 2004_CD $_$ 0.295_CD $_$ 0.255_CD $_$ 0.230_CD 494 436 398_CD Second_JJ interim_NN ,_, to_TO be_VB confirmed_VBN as_IN final_JJ ,_, payable_JJ 21_CD March_NNP 2005_CD $_$ 0.645_CD $_$ 0.540_CD $_$ 0.470_CD 1,061_CD 914_CD 808_CD $_$ 0.940_CD $_$ 0.795_CD $_$ 0.700_CD 1,555_CD 1,350_CD 1,206_CD 7_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP 2004 2003 2002_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN before_IN exceptional_JJ items_NNS $_$ m_CD 3,527_CD 3,036_CD 3,186_CD Exceptional_JJ items_NNS after_IN tax_NN $_$ m_CD see_VBP Note_NN 3_CD 286_CD 350_CD Net_JJ profit_NN for_IN the_DT financial_JJ year_NN $_$ m_CD 3,813_CD 3,036_CD 2,836_CD Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 2.11_CD $_$ 1.78_CD $_$ 1.84_CD Earnings_NNS loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ 0.17_CD $_$ 0.20_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ 2.28_CD $_$ 1.78_CD $_$ 1.64_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 2.11_CD $_$ 1.78_CD $_$ 1.84_CD Diluted_VBN earnings_NNS loss_NN per_IN Ordinary_NNP Share_NN on_IN exceptional_JJ items_NNS $_$ 0.17_CD $_$ 0.20_CD Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NNP $_$ 2.28_CD $_$ 1.78_CD $_$ 1.64_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN for_IN basic_JJ earnings_NNS millions_NNS 1,673_CD 1,709_CD 1,733_CD Dilutive_JJ impact_NN of_IN share_NN options_NNS outstanding_JJ millions_NNS 2_CD 32_CD Diluted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 1,675_CD 1,712_CD 1,735_CD There_EX are_VBP no_DT options_NNS ,_, warrants_NNS or_CC rights_NNS outstanding_JJ in_IN respect_NN of_IN unissued_JJ shares_NNS except_IN for_IN employee_NN share_NN option_NN schemes_NNS ._.
The_DT number_NN of_IN options_NNS outstanding_JJ and_CC the_DT weighted_JJ average_JJ exercise_NN price_NN of_IN these_DT options_NNS is_VBZ shown_VBN in_IN Note_NN 29_CD ._.
The_DT earnings_NNS figures_NNS used_VBN in_IN the_DT calculations_NNS above_IN are_VBP unchanged_JJ for_IN diluted_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP ._.
Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS have_VBP been_VBN calculated_VBN to_TO eliminate_VB the_DT impact_NN of_IN exceptional_JJ items_NNS on_IN the_DT results_NNS of_IN the_DT business_NN ._.
